MedTrace Logo

Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level

NCT03211403 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2018-03-21

No results posted yet for this study

Summary

This is a single-Center, randomized, double-Blind, placebo-controlled, multiple ascending-dose Phase I trail.

Conditions

  • Gout
  • Hyperuricemia

Interventions

DRUG

SHR4640

SHR4640 or placebo once daily for a week

Sponsors & Collaborators

  • Atridia Pty Ltd.

    lead INDUSTRY

Principal Investigators

  • Sam Salman, B.Sc.BMBS · Linear Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-04
Primary Completion
2018-02-15
Completion
2018-02-15

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03211403 on ClinicalTrials.gov